Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Rosenberg, O., Shoenfeld, N., Zangen, A., Kotler, M., & Dannon, P. N. (2010). Depression and anxiety, 27(5), 465-469.
This study examined the effect of the Brainsway® Deep Transcranial Magnetic Stimulation H-coil as an add-on treatment for patients suffering from drug-resistant depression. The study comprised depression patients, and treated them with Brainsway Deep Transcranial Magnetic Stimulation H1-coil, which was connected to a Magstim rapid 2 stimulator. In the study, the average HDRS and average Hamilton Anxiety Rating Scale score decreased. In this study it was demonstrated that using Deep TMS as an add-on treatment results in significant alleviation of symptoms.